Recently identified putative histidine kinase inhibitors (Velikova et al. 2016, Sci Rep and research in progress) are bactericidal against E. faecium, an opportunistic pathogen causing nosocomial infections in immunocompromised patients. We would like to explore the potential of HKI to be used as a prophylaxis therapy against E. faecium. For this, a number of in vitro and in vivo assays to study the efficacy of the HKI against E. faecium and their safety need to be performed. Afterwards, the prophylactic potential will be studied in a E. faecium colonization model in vivo in collaboration with the University of Utrecht.
Pre-clinical development of HKI as prophylaxis therapy against E. faecium.
General microbiology techniques
Antimicrobial drug development (antibacterial spectrum, MIC testing, time-kill curves, resistance development experiments, etc.)
Cell culture and toxicity testing
Nadya Velikova, firstname.lastname@example.org